other material
confidence high
sentiment positive
materiality 0.80
Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)
LISATA THERAPEUTICS, INC.
- Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
- Median OS 10.32 months (certepetide) vs 9.23 months (placebo); safety profile attractive.
- Cohort B regimen (two doses of certepetide) showed clinically meaningful improvement over Cohort A.
- Full data from both cohorts expected later 2025; presented at ESMO GI on 2 July 2025.